PMH32 COMPARISON OF REAL-WORLD HEALTH CARE COSTS AFTER THE INITIATION OF SECOND-LINE DULOXETINE OR GENERIC SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PATIENTS WITH MAJOR DEPRESSIIVE DISORDER
Abstract
Authors
R. Swindle J.I. Ivanova H.G. Birnbaum A.K. Cummings E. Kantor M. Schiller T. Clark C. Reed